Abstract: Objective The purpose of this study was to compare the virologic response in patients with chronic hepatitis C (CHC) and hepatitis C viral genotype 1b infection receiving pan-genotype or precise genotype-specific direct antiviral agent (DAA) therapy. Methods 75 patients with CHC and genotype 1b HCV infection were enrolled in our hospital between January 2018 and June 2020, and were divided into control (n=34) and study group (n=41). The patients in the control group were given the pan-genotype DAAs regimen, e.g., sofibovir/vapatavir in 19 cases and sufosbuvir/ velpatasvir in 15 cases, and the patients in the study group received precise genotype-specific DAAs regimen, e.g., elbasvir/grazoprevir in 23 cases, and ombitasvir/dasabuvir in 18 cases. The antiviral treatment lasted for 12 weeks. The super-rapid virologic response (SRVR), rapid virologic response (RVR), early virologic response (EVR) and sustained virologic response (SVR) were compared between the two groups. Results At the end of 12 week treatment, serum ALT and AST levels in the study group were (31.9±4.1)U/L and (32.5±4.1)U/L, not significantly different compared to (32.7±4.2)U/L and (31.9±3.7)U/L (P＞0.05) in the control group; the SRVR, RVR, EVR and SVR in the study group were 87.8%, 97.6%, 100.0% and 100.0%, all not significantly different compared to 88.2%, 94.1%, 100.0% and 100.0% in the control (P＞0.05); the SRVR, RVR, EVR and SVR in sofibovir/vapatavir-treated patients were 84.2%, 100.0%, 100.0% and 100.0%, those in sufosbuvir/ velpatasvir-treated patients were 86.7%, 93.3%, 100.0% and 100.0%, in elbasvir/grazoprevir-treated patients were 91.3%, 100.0%, 100.0% and 100.0%, and in ombitasvir/dasabuvir-treated patients were 88.9%, 94.4%, 100.0% and 100.0%, all not significantly different among the four groups(P＞0.05); the incidences of complications during the antiviral treatment were 11.8% vs. 12.2% between the two groups (P＞0.05). Conclusion At present, the pan-genotype and precise genotype- specific DAAs regimens both have a very good antiviral efficacy in CHC patients with genotype 1b infection, with a pleasant safety.

Key words: Hepatitis C, Direct antiviral agents, Genotype 1b, Therapy